Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
31 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Pipeline Review, H2 2016', provides in depth analysis on Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted pipeline therapeutics. The report provides comprehensive information on the Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - The report reviews Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics and enlists all their major and minor projects - The report assesses Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) Overview 6 Therapeutics Development 7 Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Products under Development by Stage of Development 7 Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Products under Development by Therapy Area 8 Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Products under Development by Indication 9 Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Pipeline Products Glance 10 Early Stage Products 10 Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Products under Development by Companies 11 Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Therapeutics Assessment 13 Assessment by Monotherapy/Combination Products 13 Assessment by Mechanism of Action 14 Assessment by Route of Administration 15 Assessment by Molecule Type 16 Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Companies Involved in Therapeutics Development 17 Mateon Therapeutics Inc 17 Phelix Therapeutics, LLC 18 Virobay Inc. 19 Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Drug Profiles 20 Drugs to Inhibit Cathepsin L for Infectious Diseases - Drug Profile 20 Product Description 20 Mechanism Of Action 20 R&D Progress 20 KGP-94 - Drug Profile 21 Product Description 21 Mechanism Of Action 21 R&D Progress 21 VBY-129 - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 VBY-285 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 VBY-825 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 VBY-X - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Dormant Projects 26 Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Featured News & Press Releases 27 Apr 07, 2014: OXiGENE Announces Results of KGP94 Preclinical Studies at 2014 AACR Conference 27 Mar 27, 2014: OXiGENE Announces Presentation of Preclinical Abstracts at 2014 AACR Conference 27 Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model 28 Appendix 30 Methodology 30 Coverage 30 Secondary Research 30 Primary Research 30 Expert Panel Validation 30 Contact Us 30 Disclaimer 31
List of Tables
Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Indication, H2 2016 9 Comparative Analysis by Early Stage Products, H2 2016 10 Number of Products under Development by Companies, H2 2016 11 Products under Development by Companies, H2 2016 12 Assessment by Monotherapy/Combination Products, H2 2016 13 Number of Products by Stage and Mechanism of Action, H2 2016 14 Number of Products by Stage and Route of Administration, H2 2016 15 Number of Products by Stage and Molecule Type, H2 2016 16 Pipeline by Mateon Therapeutics Inc, H2 2016 17 Pipeline by Phelix Therapeutics, LLC, H2 2016 18 Pipeline by Virobay Inc., H2 2016 19 Dormant Projects, H2 2016 26
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.